Endoscopic balloon dilatation of Crohn's disease strictures: results from a large United kingdom series.

Introduction: Stricturing is a common complication of Crohn's disease. Endoscopic balloon dilatation (EBD) offers a valuable alternative to surgical intervention, but there are limited data on factors influencing its safety and efficacy.

Methods: A multicenter retrospective audit across 4 U.

Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?

Background: Adalimumab (ADA) is a subcutaneous anti-tumour necrosis factor (anti-TNF) agent, effective in inducing and maintaining remission in Crohn's disease (CD). Unlike Infliximab (IFX), ADA dosing is not weight adjusted and dose frequency is based on clinical response.

Aim: To determine whether obesity is a risk factor for early loss of response (LOR) to anti-TNF treatment and whether weight-adjusted anti-TNF treatment is favourable.

Paraneoplastic oesophageal dysmotility-renal cell carcinoma presenting as dysphagia: a case report.

Introduction: Dysphagia and weight loss are alarming symptoms that warrant urgent assessment.

Case Presentation: We present a case report of dysphagia secondary to oesophageal dysmotility attributed to a paraneoplastic manifestation of an occult renal cell carcinoma.

Conclusion: We believe this patient's dysphagia was a paraneoplastic manifestation of the renal cell tumour, an association that has never been previously reported.